FDA

Latest News

FDA Approves Amvuttra for ATTR-CM in Extended Label
FDA Approves Amvuttra for ATTR-CM in Extended Label

March 21st 2025

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Berit Kessler-stock.adobe.com
FDA Approves Tremyfa to Treat Active Crohn’s Disease

March 21st 2025

scientific image of kidney | image credit: ©crystal light
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G

March 21st 2025

Vitalii Vodolazskyi-stock.adobe.com
FDA Grants Priority Review to Kerendia in Heart Failure

March 17th 2025

Tatiana Shepeleva-stock.adobe.com
FDA Approves First Generics of Xarelto

March 12th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.